Title: Abarelix
CAS Registry Number: 183552-38-7
CAS Name: N-Acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-N-methyl-L-tyrosyl-D-asparaginyl-L-leucyl-N6-(1-methylethyl)-L-lysyl-L-prolyl-D-alaninamide
Additional Names: Ac-D-Nal1-4-Cl-D-Phe2-D-Pal3-N-Me-Tyr5-D-Asn6-Lys(iPr)8-D-Ala10-LH-RH
Manufacturers' Codes: PPI-149
Trademarks: Plenaxis (Praecis)
Molecular Formula: C72H95ClN14O14
Molecular Weight: 1416.06
Percent Composition: C 61.07%, H 6.76%, Cl 2.50%, N 13.85%, O 15.82%
Literature References: Decapeptide LH-RH antagonist. Prepn: R. W. Roeske, WO 9640757 (1996 to Indiana Univ. Found.); idem, US 5843901 (1998 to Adv. Res. Technol. Inst.). Pharmacology and suppression of plasma gonadotropins: C. J. Molineaux et al., Mol. Urol. 2, 265 (1998). Clinical comparison with leuprolide in prostate cancer: J. Trachtenberg et al., J. Urol. 167, 1670 (2002). Clinical pharmacology: S. L. Wong et al., Clin. Pharmacol. Ther. 73, 304 (2003); of depot formulation: eidem, J. Clin. Pharmacol. 44, 495 (2004). Review of clinical development: P. Mongiat-Artus, P. Teillac, Expert Opin. Pharmacother. 5, 2171-2179 (2004).
Properties: White solid. Sol in water.
Therap-Cat: Antineoplastic (hormonal).
Keywords: Antineoplastic (Hormonal); LH-RH Analogs.
Abatacept Abciximab Abecarnil Abetimus Sodium Abietic Acid

Systematic (IUPAC) name
acetyl-D-β-naphthylalanyl- D-4-chlorophenylalanyl-D-3-pyridylalanyl-L-seryl-L- N-methyl- tyrosyl-D-asparagyl-L-leucyl-L-N(e )-isopropyl-lysyl-L-prolyl-D-alanyl-amide
Clinical data
Trade names Plenaxis
AHFS/Drugs.com monograph
Pregnancy cat. X (US)
Legal status  ?
Routes Intramuscular injection
Pharmacokinetic data
Protein binding 96–99%
CAS number 183552-38-7 N
ATC code L02BX01
PubChem CID 16131215
IUPHAR ligand 1188
DrugBank DB00106
ChemSpider 10482301 YesY
UNII W486SJ5824 YesY
KEGG D02738 YesY
ChEBI CHEBI:337298 YesY
Chemical data
Formula C72H95ClN14O14 
Mol. mass 1416.06 g/mol
 N (what is this?)  (verify)

Abarelix (trade name Plenaxis) is an injectable gonadotropin-releasing hormone antagonist (GnRH antagonist). It is primarily used in oncology to reduce the amount of testosterone made in patients with advanced symptomatic prostate cancer for which no other treatment options are available.[1][2]

It was originally marketed by Praecis Pharmaceuticals as Plenaxis,[1] and is now marketed by Speciality European Pharma in Germany[3] after receiving a marketing authorisation in 2005.